Physician profile

Daniel J Steier

Family Medicine · Omaha, NE

NPI 1265582266

$1,412.60

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $192.36 2019-2021
Amarin Pharma, INC. $167.56 2019-2021
Boston Scientific Corporation $164.31 2019-2022
Astrazeneca Pharmaceuticals Lp $109.79 2019
Amgen INC. $109.00 2019-2021
Sanofi-Aventis U.S. LLC $95.40 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $88.61 2019-2021
Pfizer INC. $57.90 2019-2021
Biohaven Pharmaceuticals, INC. $52.92 2021
Astellas Pharma US INC $51.83 2019-2021
Lilly USA, LLC $38.15 2021
Abbvie INC. $35.73 2019-2021
Glaxosmithkline, LLC. $33.87 2021
Gilead Sciences, INC. $32.78 2019
Allergan, INC. $32.56 2019-2020
Show all 25 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel J Steier

$1,412.60

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/330142/daniel-j-steier

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.